LXRX today
$1.87+$0.01 (+0.54%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourBearish
15 minBearish
5 minSymmetric Triangle
Daily trend turns up above $2.05
Key levels
Resistance$2.05
Resistance$1.89
Support$1.76
Support$1.65
Latest news & SEC filings
AnalystCitigroup raises its price target on Lexicon Pharmaceuticals
AnalystCitigroup keeps Buy rating on Lexicon Pharmaceuticals, lifts target to $3.4
ProductLexicon Pharmaceuticals presents new sotagliflozin data at AHA Scientific Sessions 2026
All LXRX news →About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biopharmaceutical company that discovers and develops orally taken small-molecule medicines. Its approved drug, INPEFA (sotagliflozin), is sold in the United States for patients with heart failure, type 2 diabetes and chronic kidney disease. The company is also developing sotagliflozin for hypertrophic cardiomyopathy and type 1 diabetes, pilavapadin for neuropathic pain, and LX9851 for obesity, which is licensed to Novo Nordisk. It operates mainly in the United States and uses outside manufacturers.
Based on the company's 10-K filed Mar 5, 2026.
Nasdaq · Healthcare
LEXICON PHARMACEUTICALS, INC. (LXRX)
What Is the Price Target for LXRX?
SEPT Low Target
$3.10
SEPT Mid Target
$8.00
SEPT High Target
$8.00
Analyst Consensus
$8.00
Is LXRX a Buy or Sell Right Now?
Thesis
- •Revenue growing 60.2% YoY with STRONG trend — consistent growth.
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for LXRX.
Start Free Trial →Is LXRX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$6.26
20
Moat Score
NONE
3/9
Piotroski Score
-11.2
Altman Z-Score
What Is Smart Money Doing with LXRX?
Insider Signal
BUYING
7 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Swain Judith L | director | Buy | 89,312 | - | Jun 3, 2026 |
| Sullivan Diane E. | director | Buy | 89,312 | - | Jun 3, 2026 |
| SOBECKI CHRISTOPHER J | director | Buy | 89,312 | - | Jun 3, 2026 |
| Cheung Ivan | director | Buy | 89,312 | - | Jun 3, 2026 |
| BARKER SAM L | director | Buy | 89,312 | - | Jun 3, 2026 |
| Amouyal Philippe | director | Buy | 89,312 | - | Jun 3, 2026 |
| DEBBANE RAYMOND | director | Buy | 89,312 | - | Jun 3, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →LXRX Growth Story
Revenue YoY
60.2%
3yr Revenue CAGR
610.3%
EPS Growth YoY
77.78%
FCF Growth YoY
62.3%
Revenue Trend
STRONG
Dark Pool Trades for LXRX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for LXRX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:30:51 | $1.87 | 1,330,080 | $$2.5M | BUY |
| 21:01:37 | $1.87 | 1,438 | $$3K | MIDPOINT |
| 21:01:27 | $1.87 | 41,156 | $$77K | MIDPOINT |
| 21:00:02 | $1.87 | 5,700 | $$11K | MIDPOINT |
| 21:00:02 | $1.87 | 1,500 | $$3K | MIDPOINT |
5 dark pool trades shown · $$2.6M preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for LEXICON PHARMACEUTICALS, INC. (LXRX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →LXRX — frequently asked questions
What is LXRX stock price today?
LEXICON PHARMACEUTICALS, INC. (LXRX) is at $1.87, up 0.54% (+$0.01) at the Nov 11, 2026 close.
Why is LXRX stock moving today?
Latest LXRX news — Nov 9, 2026: Citigroup raises its price target on Lexicon Pharmaceuticals · Nov 9, 2026: Citigroup keeps Buy rating on Lexicon Pharmaceuticals, lifts target to $3.4
What is the LXRX price target?
The average analyst price target for LXRX is $8.00, ranging from $3 to $8, based on 3 analysts. Latest: Lexicon Pharmaceuticals upgrade on Sep 28, 2026.
What do analysts rate LXRX?
Analyst ratings for LXRX: 0 Buy, 3 Hold, 0 Sell — consensus Hold.
Did LXRX beat earnings?
LXRX last reported on Aug 6, 2026: EPS -$0.06 vs -$0.05 expected — a miss of 19.5%.
Does LXRX pay a dividend?
LXRX does not currently pay a dividend.
What are LXRX support and resistance levels?
Support: $1.76, $1.65, $1.52. Resistance: $1.89, $2.05, $2.17.
What are insiders doing with LXRX?
Insider activity: BUYING, 7 buys and 0 sells in the last 90 days.
What is the latest news on LXRX?
Nov 9, 2026: Citigroup raises its price target on Lexicon Pharmaceuticals · Nov 9, 2026: Citigroup keeps Buy rating on Lexicon Pharmaceuticals, lifts target to $3.4 · Nov 9, 2026: Lexicon Pharmaceuticals presents new sotagliflozin data at AHA Scientific Sessions 2026